Latest news with #ScientificSessions
Yahoo
18-07-2025
- Business
- Yahoo
Abbott lowers sales forecast on diagnostics decline, US funding cuts
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $11.14 billion 7.4% increase year over year Medical device sales: $5.37 billion 13.4% increase year over year Diagnostics sales: $2.17 billion 1% decrease year over year Abbott lowered its sales forecast for the year, citing a drop in diagnostic testing. CEO Robert Ford told investors on Thursday that the company is seeing a drop-off in COVID-19 testing sales, challenges in China's core laboratory market and a reduction in U.S. foreign aid funding for HIV testing, with a combined impact of more than $1 billion. The company reduced its 2025 organic sales growth forecast to a range of 6% to 7%, from the previous forecast of 7.5% to 8.5% shared in the first quarter. 'Even with that billion dollars, we're still forecasting high single-digit growth and absorbing the impact of tariffs,' Ford said. The company now expects 'just under $200 million' of impact from tariffs. CFO Phil Boudreau said the amount was down from previous estimates, when the company had outlined 'a few hundred million' in tariff costs. Discussing how the company plans to mitigate tariffs, Ford said that Abbott plans to open a new cardiovascular manufacturing facility in Georgia in 2028. 'Once tariffs get set in place, they're very difficult to walk away from,' the CEO said, 'so we have to think medium term, but also long term.' Growth in medical devices, diabetes A bright spot for Abbott was its medical device segment, which grew by more than 13% to $5.37 billion in sales. The company's diabetes segment grew by more than 20% to $1.98 billion. Analysts asked about Abbott's plans for a dual analyte sensor that would provide glucose and ketone readings. The company recently showcased the device during the American Diabetes Association's Scientific Sessions. Ford declined to provide a timeline or pricing details for the planned device. BTIG analyst Marie Thibault wrote in June that Abbott's management expects a launch sometime next year. The company is also partnering with insulin pump companies, including Tandem, Sequel Med Tech and Beta Bionics, to support the new sensor. 'I think this is going to be a real next-level, significant change in the CGM market,' Ford said, specifically for intensive insulin users. Abbott's electrophysiology business, with the company's new Volt pulsed field ablation device to treat cardiac arrhythmias, grew by 11.5% to $700 million. Recommended Reading 'We are not rolling over': J&J electrophysiology unit rebounds amid PFA rivalry Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Mint
14-07-2025
- Health
- Mint
Sugar.fit's Research Accepted at the American Diabetes Association's 85th Scientific Sessions in Chicago
Bangalore, Karnataka, India – Business Wire India is proud to announce that four pioneering research abstracts were accepted for poster presentation at the American Diabetes Association's® 85th Scientific Sessions, held in Chicago. Dr. Chhavi Mehra, Chief Medical Officer at said, ' research is driving personalized diabetes management, and we're excited to share our findings with the global community.' The accepted abstracts, presented by Shivtosh Kumar, Chief Product Officer and Co-founder of span critical domains in diabetes care, from emotional well-being to AI-driven personalized care. The studies emphasize real-world outcomes and innovative solutions. Interim Analysis of a Multicenter, Randomized Controlled Trial: Evaluating the effectiveness of personalized coaching program combining continuous glucose monitoring (CGM), nutrition, fitness, and mental wellness, showing significant improvements in HbA1c, fasting glucose, and weight. Revolutionizing Diabetes Care with AI: Introduction of RAGUS AI, a GPT-powered chatbot delivering personalized diabetes care at scale, demonstrating clinical utility in early testing. Evaluating the Spectrum of Emotional Distress in Diabetes: Investigating the link between emotional distress and glycemic control, with findings showing that psychosocial interventions can improve outcomes. Real-World Impact of AI-Driven CGM Platform: Assessing the clinical impact of AI-powered CGM platform, showing improvements in HbA1c, fasting glucose, and body weight. Looking Ahead: Empowering the Future of Diabetes Care Shivtosh Kumar, Co-founder of stated, 'These abstracts reflect our ongoing efforts to revolutionize diabetes care through technology and personalized support. We are excited to continue advancing diabetes management on a national scale.' Annie Mattilda Raymond, Head of Research and Development at added, 'With a cohort of nearly 80,000 users, our aim is to produce high-quality, real-world data that demonstrates how our evidence-based approach can lead to sustainable lifestyle changes and improved health outcomes.' remains committed to making diabetes care more accessible, effective, and sustainable through the integration of AI, continuous monitoring, and behavioral science. About Ragus Healthcare Pvt. Ltd. ( Ragus Healthcare Pvt. Ltd. ( is a healthcare technology company that is transforming diabetes care through its flagship program. provides personalized, tech-enabled diabetes management, coupled with AI-driven recommendations and expert human coaching. The company's mission is to make diabetes care more affordable, accessible, and outcome-driven for people across India and beyond. is backed by B Capital, Mass Mutual Ventures, Endiya Partners, Tanglin Venture Partners and Curefit. Disclaimer: This article is a paid publication and does not have journalistic/editorial involvement of Hindustan Times. Hindustan Times does not endorse/subscribe to the content(s) of the article/advertisement and/or view(s) expressed herein. Hindustan Times shall not in any manner, be responsible and/or liable in any manner whatsoever for all that is stated in the article and/or also with regard to the view(s), opinion(s), announcement(s), declaration(s), affirmation(s) etc., stated/featured in the same.
NDTV
14-07-2025
- Health
- NDTV
Sugar.fit's Research Accepted At The American Diabetes Association's 85th Scientific Sessions In Chicago
Bangalore, Karnataka, India - Business Wire India is proud to announce that four pioneering research abstracts were accepted for poster presentation at the American Diabetes Association's 85th Scientific Sessions, held in Chicago. Dr. Chhavi Mehra, Chief Medical Officer at said, " research is driving personalized diabetes management, and we're excited to share our findings with the global community." The accepted abstracts, presented by Shivtosh Kumar, Chief Product Officer and Co-founder of span critical domains in diabetes care, from emotional well-being to AI-driven personalized care. The studies emphasize real-world outcomes and innovative solutions. Accepted Abstracts: Interim Analysis of a Multicenter, Randomized Controlled Trial: Evaluating the effectiveness of personalized coaching program combining continuous glucose monitoring (CGM), nutrition, fitness, and mental wellness, showing significant improvements in HbA1c, fasting glucose, and weight. Revolutionizing Diabetes Care with AI: Introduction of RAGUS AI, a GPT-powered chatbot delivering personalized diabetes care at scale, demonstrating clinical utility in early testing. Evaluating the Spectrum of Emotional Distress in Diabetes: Investigating the link between emotional distress and glycemic control, with findings showing that psychosocial interventions can improve outcomes. Real-World Impact of AI-Driven CGM Platform: Assessing the clinical impact of AI-powered CGM platform, showing improvements in HbA1c, fasting glucose, and body weight. Looking Ahead: Empowering the Future of Diabetes Care Shivtosh Kumar, Co-founder of stated, "These abstracts reflect our ongoing efforts to revolutionize diabetes care through technology and personalized support. We are excited to continue advancing diabetes management on a national scale." Annie Mattilda Raymond, Head of Research and Development at added, "With a cohort of nearly 80,000 users, our aim is to produce high-quality, real-world data that demonstrates how our evidence-based approach can lead to sustainable lifestyle changes and improved health outcomes." remains committed to making diabetes care more accessible, effective, and sustainable through the integration of AI, continuous monitoring, and behavioral science. About Ragus Healthcare Pvt. Ltd. ( Ragus Healthcare Pvt. Ltd. ( is a healthcare technology company that is transforming diabetes care through its flagship program. provides personalized, tech-enabled diabetes management, coupled with AI-driven recommendations and expert human coaching. The company's mission is to make diabetes care more affordable, accessible, and outcome-driven for people across India and beyond. is backed by B Capital, Mass Mutual Ventures, Endiya Partners, Tanglin Venture Partners and Curefit.
Business Wire
25-06-2025
- Health
- Business Wire
Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects
DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma ('Metabolics'), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced top-line data from a Phase 1a clinical trial of its drug candidate, ENT-03, in obese and diabetic patients. ENT-03 was found to be safe and well tolerated at all doses evaluated as presented at the American Diabetes Association 85 th Scientific Sessions on June 22, 2025. The study results showed positive trends for both weight reduction and increased insulin sensitivity at higher tested doses. Metabolics Pharma Announces Positive Top-Line Results from Phase 1a Clinical Trial of ENT-03 in Obese and Diabetic Subjects Share ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by acting on brain circuits that regulate energy and metabolism. In addition to the clinical trial results, ENT-03 is effective as a monotherapy and has an additive effect in combination with GLP1 agonists in animal models. ENT-03 also demonstrates durable weight loss and glucose and insulin normalization after therapy cessation. 'Our first-in-human study has demonstrated that ENT-03 is safe and very well tolerated and showed positive trends in both weight loss and insulin sensitivity that are consistent with what we have seen in preclinical in vivo studies,' said Richard Larson, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of Metabolics Pharma. 'We are planning a Phase 1b study to evaluate dosing regimens, which we expect to initiate in the second half of 2025.' The Phase 1a clinical trial was a single ascending dose study evaluating seven dose cohorts of ENT-03 in healthy obese subjects and obese subjects with type 2 diabetes (T2D). ENT-03 was administered subcutaneously (SQ) at six different doses. The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days. More information can be found on ENT-03 was very well tolerated and efficacy endpoints showed trends toward weight loss at higher doses for both obese and obese/T2D subjects, along with improvement in insulin sensitivity. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity, type 2 diabetes, and MASH. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit
Business Insider
24-06-2025
- Health
- Business Insider
Corcept says Catalyst trial met primary endpoint
Corcept Therapeutics (CORT) Incorporated presented data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial of Korlym in patients with hypercortisolism and difficult-to-control type 2 diabetes at the American Diabetes Association's 85th Scientific Sessions. CATALYST met its primary endpoint. Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c, which decreased 1.47 percent from baseline, compared to a 0.15 percent decrease in patients who received placebo. Of the 91 patients in the treatment group, 65received at least 600mg of Korlym and 28 received 900mg. Patients who received 900mg of Korlym had an improvement in HbA1c of 2.01 percent, compared to a 0.16 percent decrease in patients who received placebo. The trial also met its secondary endpoints, as patients who received Korlym exhibited significantly reduced body weight and waist circumference, compared to patients who received placebo. Patients receiving Korlym achieved these improvements despite reducing or discontinuing their glucose-lowering medications. Adverse events in CATALYST were manageable and consistent with Korlym's known safety profile. The most common adverse events were hypokalemia, fatigue and nausea.
